BRPI0616944B8 - compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem - Google Patents

compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem

Info

Publication number
BRPI0616944B8
BRPI0616944B8 BRPI0616944A BRPI0616944A BRPI0616944B8 BR PI0616944 B8 BRPI0616944 B8 BR PI0616944B8 BR PI0616944 A BRPI0616944 A BR PI0616944A BR PI0616944 A BRPI0616944 A BR PI0616944A BR PI0616944 B8 BRPI0616944 B8 BR PI0616944B8
Authority
BR
Brazil
Prior art keywords
compounds
diseases
modulation
treatment
prolinamide
Prior art date
Application number
BRPI0616944A
Other languages
English (en)
Portuguese (pt)
Inventor
Alvaro Giuseppe
Bergauer Markus
Giovannini Riccardo
Profeta Roberto
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0520581A external-priority patent/GB0520581D0/en
Priority claimed from GB0523045A external-priority patent/GB0523045D0/en
Priority claimed from GB0603900A external-priority patent/GB0603900D0/en
Priority claimed from GB0618336A external-priority patent/GB0618336D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0616944A2 publication Critical patent/BRPI0616944A2/pt
Publication of BRPI0616944B1 publication Critical patent/BRPI0616944B1/pt
Publication of BRPI0616944B8 publication Critical patent/BRPI0616944B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0616944A 2005-10-10 2006-10-06 compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem BRPI0616944B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0520581.0 2005-10-10
GB0520581A GB0520581D0 (en) 2005-10-10 2005-10-10 Novel compounds
GB0523045.3 2005-11-11
GB0523045A GB0523045D0 (en) 2005-11-11 2005-11-11 Novel compounds
GB0603900.2 2006-02-27
GB0603900A GB0603900D0 (en) 2006-02-27 2006-02-27 Novel compounds
GB0618336A GB0618336D0 (en) 2006-09-18 2006-09-18 Novel compounds
GB0618336.2 2006-09-18
PCT/EP2006/009731 WO2007042239A1 (en) 2005-10-10 2006-10-06 Prolinamide derivatives as sodium channel modulators

Publications (3)

Publication Number Publication Date
BRPI0616944A2 BRPI0616944A2 (pt) 2011-07-05
BRPI0616944B1 BRPI0616944B1 (pt) 2020-04-14
BRPI0616944B8 true BRPI0616944B8 (pt) 2021-05-25

Family

ID=37546777

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616944A BRPI0616944B8 (pt) 2005-10-10 2006-10-06 compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem

Country Status (20)

Country Link
US (2) US7655693B2 (https=)
EP (1) EP1934177B8 (https=)
JP (1) JP5139305B2 (https=)
KR (1) KR101282464B1 (https=)
AR (1) AR056575A1 (https=)
AT (1) ATE556049T1 (https=)
AU (1) AU2006301470B2 (https=)
BR (1) BRPI0616944B8 (https=)
CA (1) CA2625642C (https=)
CR (1) CR9898A (https=)
EA (1) EA015736B1 (https=)
ES (1) ES2387405T3 (https=)
IL (1) IL192627A0 (https=)
MA (1) MA29817B1 (https=)
NO (1) NO20082145L (https=)
NZ (1) NZ567051A (https=)
PE (1) PE20070592A1 (https=)
PL (1) PL1934177T3 (https=)
TW (1) TW200730494A (https=)
WO (1) WO2007042239A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143306B2 (en) * 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
GB0701365D0 (en) * 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
EP2461807A1 (en) * 2009-08-05 2012-06-13 Convergence Pharmaceuticals Limited Co-therapy for the treatment of epilepsy and related disorders
DK2477964T5 (en) * 2009-09-14 2015-05-26 Convergence Pharmaceuticals A process for the preparation of alpha-carboxamide
CA2828456C (en) 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
CA2936886A1 (en) 2014-02-27 2015-08-03 Merck Patent Gmbh Heterocyclic compounds as nav channel inhibitors and uses thereof
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
ES2912881T3 (es) * 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
AU2017353841A1 (en) * 2016-11-02 2019-05-30 Biogen Ma Inc. Novel dosage regimen
AU2018269924B2 (en) * 2017-05-19 2022-07-07 Biogen Ma Inc. Novel crystalline forms
US11192856B2 (en) * 2017-10-05 2021-12-07 Biogen Inc. Process for preparing alpha-carboxamide pyrrolidine derivatives
US11149039B2 (en) 2017-10-10 2021-10-19 Biogen Inc. Process for preparing spiro derivatives
CA3093401A1 (en) * 2018-04-16 2019-10-24 Biogen Ma Inc. Methods of treating neuropathic pain
WO2020210486A1 (en) * 2019-04-10 2020-10-15 Biogen Inc. Processes for preparing alpha-carboxamide pyrrolidine derivatives
CN114026066A (zh) * 2019-04-10 2022-02-08 生物基因麻省公司 制备α-甲酰胺吡咯烷衍生物的方法
WO2021154631A1 (en) 2020-01-30 2021-08-05 Javed Mohammad Combination drug therapies for cns disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6136131A (en) * 1998-06-02 2000-10-24 Instrument Specialties Company, Inc. Method of shielding and obtaining access to a component on a printed circuit board
TW502019B (en) 1999-03-26 2002-09-11 Cocensys Inc Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
TW200404796A (en) * 2002-08-19 2004-04-01 Ono Pharmaceutical Co Nitrogen-containing compound
PE20050077A1 (es) 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US7589116B2 (en) 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
CA2522476A1 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
EP1524265A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
WO2005100334A1 (en) 2004-04-14 2005-10-27 Pfizer Products Inc. Dipeptidyl peptidase-iv inhibitors
WO2006119390A1 (en) 2005-05-04 2006-11-09 Vertex Pharmaceuticals Incorporated Pyridines useful as modulators of ion channels
JP2008540443A (ja) 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なピリミジンおよびピラジン
JP2008540665A (ja) 2005-05-19 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとして有用なビアリール
EA013909B1 (ru) 2005-09-09 2010-08-30 Смитклайн Бичам Корпорейшн Пиридиновые производные и их применение для лечения психотических расстройств
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
EA200801054A1 (ru) 2008-08-29
AU2006301470B2 (en) 2012-06-14
US20080280969A1 (en) 2008-11-13
US7655693B2 (en) 2010-02-02
US20100105754A1 (en) 2010-04-29
EP1934177B1 (en) 2012-05-02
AU2006301470A1 (en) 2007-04-19
CA2625642C (en) 2013-12-24
NO20082145L (no) 2008-05-07
KR20080059296A (ko) 2008-06-26
IL192627A0 (en) 2011-08-01
PE20070592A1 (es) 2007-06-23
BRPI0616944B1 (pt) 2020-04-14
PL1934177T3 (pl) 2013-03-29
CA2625642A1 (en) 2007-04-19
WO2007042239A1 (en) 2007-04-19
ATE556049T1 (de) 2012-05-15
US8153681B2 (en) 2012-04-10
EA015736B1 (ru) 2011-10-31
JP2009511519A (ja) 2009-03-19
KR101282464B1 (ko) 2013-07-04
BRPI0616944A2 (pt) 2011-07-05
ES2387405T3 (es) 2012-09-21
EP1934177A1 (en) 2008-06-25
AR056575A1 (es) 2007-10-10
JP5139305B2 (ja) 2013-02-06
TW200730494A (en) 2007-08-16
EP1934177B8 (en) 2012-09-05
NZ567051A (en) 2011-03-31
CR9898A (es) 2008-07-29
MA29817B1 (fr) 2008-09-01

Similar Documents

Publication Publication Date Title
BRPI0616944B8 (pt) compostos derivados de prolinamida moduladores do canal de sódio, composição farmacêutica compreendendo os ditos compostos, bem como seus processos de preparação e uso no tratamento ou prevenção de doenças e condições mediadas pela modulação de canais de sódio dependentes de voltagem
BRPI0916735B8 (pt) compostos moduladores de tgr5, composições farmacêuticas compreendendo os mesmos e seus usos
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA201000886A1 (ru) Органические соединения
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
ATE517882T1 (de) Chinolinderivate
GEP20125643B (en) Aurora kinase modulators and method of using same
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
DK1853602T3 (da) Kemiske forbindelser
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MX2009011533A (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
EA201001772A1 (ru) Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
TW200626158A (en) Naphthaline derivatives
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2795 DE 30-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.